0
Letters |

NMP22 and Surveillance for Recurrent Bladder CancerNMP22 and Surveillance for Recurrent Bladder Cancer

JAMA. 2006;296(1):44-46. doi:10.1001/jama.296.1.44-b
Text Size: A A A
Published online

AUTHOR INFORMATION

Letters Section Editor: Robert M. Golub, MD, Senior Editor.

NMP22 AND SURVEILLANCE FOR RECURRENT BLADDER CANCER

To the Editor: The results of the study of the NMP22 assay for bladder cancer surveillance by Dr Grossman and colleagues1 do not justify adopting this test for such use. First, the assessment of the sensitivity and specificity of the NMP22 assay was flawed. Diagnostic test evaluation requires the uniform application of an unambiguous reference standard.2 The authors used the reference standard of cystoscopy, but it is unclear how often it was applied. The cross-sectional design of the study implies that all patients underwent a single cystoscopy at the time of NMP22 testing. However, at least 9 patients—and as many as 574 not diagnosed as having cancer at their initial cystoscopy—also underwent repeat cystoscopy. If not all 574 patients underwent a repeat examination, then the reference standard was applied inconsistently, raising questions about whether the NMP22 result prompted the repeat cystoscopy, thus inflating the sensitivity of the NMP22 assay (workup bias).

Even if the reference standard were applied uniformly, it is difficult to understand what a recommended strategy for the use of NMP22 would be. Its low sensitivity (49.5%) argues against its use as an alternative to cystoscopy. The strategy of using the NMP22 assay in conjunction with the initial cystoscopy provides no advantage, since adding the NMP22 assay apparently had no role in identifying the 9 additional cancers (4 of which were found because of increased symptoms and 5 because of “close monitoring”). But adding the NMP22 assay does increase false alarms (false-positive rate of 13%). Alternatively, the strategy of using NMP22 as a monitoring tool between cystoscopies, suggested by the authors, was not examined in this study.

The goal of surveillance is to reduce bladder cancer mortality, not simply to find more cancer. The larger question of whether routine surveillance for bladder cancer reduces bladder cancer mortality remains unaddressed.3 4

Financial Disclosures: None reported.

References
Grossman HB, Soloway M, Messing E.  et al.  Surveillance for recurrent bladder cancer using a point-of-care proteomic assay.  JAMA. 2006;295299-305
PubMed
Jaeschke R, Guyatt GH, Sackett DL.Evidence-Based Medicine Working Group.  How to use an article about a diagnostic test, B: what are the results and will they help me in caring for my patients?  JAMA. 1994;271703-707
PubMed
National Comprehensive Cancer Network.  Bladder Cancer: Including Upper Tract Tumors and Urothelial Carcinoma of the ProstateVersion 1.2006. Jenkintown, Pa: National Comprehensive Cancer Network; November 9, 2005. Clinical Practice Guidelines in Oncology series
Schrag D, Hsieh LJ, Rabbani F, Bach PB, Herr H, Begg CB. Adherence to surveillance among patients with superficial bladder cancer.  J Natl Cancer Inst. 2003;95588-597
PubMed

First Page Preview

First page PDF preview

Figures

Tables

Interactive Graphics

Video

Country-Specific Mortality and Growth Failure in Infancy and Yound Children and Association With Material Stature

Use interactive graphics and maps to view and sort country-specific infant and early dhildhood mortality and growth failure data and their association with maternal

Grossman HB, Soloway M, Messing E.  et al.  Surveillance for recurrent bladder cancer using a point-of-care proteomic assay.  JAMA. 2006;295299-305
PubMed
Jaeschke R, Guyatt GH, Sackett DL.Evidence-Based Medicine Working Group.  How to use an article about a diagnostic test, B: what are the results and will they help me in caring for my patients?  JAMA. 1994;271703-707
PubMed
National Comprehensive Cancer Network.  Bladder Cancer: Including Upper Tract Tumors and Urothelial Carcinoma of the ProstateVersion 1.2006. Jenkintown, Pa: National Comprehensive Cancer Network; November 9, 2005. Clinical Practice Guidelines in Oncology series
Schrag D, Hsieh LJ, Rabbani F, Bach PB, Herr H, Begg CB. Adherence to surveillance among patients with superficial bladder cancer.  J Natl Cancer Inst. 2003;95588-597
PubMed
CME Course for:


You need to register in order to view this quiz.


To understand the clinical management of acute heart failure syndromes.
Accreditation Information The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
To view and print your certificate and access a summary of your CME courses go to My CME.
NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s “Cited By” API will populate this tab (http://www.crossref.org/citedby.html).
Submit a Response

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.